What is it about?

Disorders of Central Nervous System (CNS) include such devastating conditions as Alzheimer's, Parkinson's disease, depression, schizophrenia, autism, and others. The success rates of the CNS drug-discovery programs is particularly low, which resulted in a number of pharmaceutical companies withdrawing from CNS field, in the face of an epidemics of Alzheimer's disease and other forms of dementia in the aging population in the developed world. This paper, written by multidisciplinary team of scientists, regulators and clinicians, is proposing a new framework for drug discovery of CNS drugs, which is intended to make the process more rigorous and objective, and ultimately, will result in reductions in late attrition and approval of more medicines for many devastating CNS disorders.

Featured Image

Why is it important?

Drug-discovery is a complex process, which involves understanding the interconnected biological processes and the use of multiple model systems to manipulate a pathway that is involved in causing a disease. It involves close collaboration between biologists, chemists, toxicologists, pharmacologists, physicians, representing academia, regulatory bodies and pharmaceutical companies. This process is particularly complicated in the CNS field, where access to the tissue in humans is limited. We propose here a new rigorous and objective framework, termed quantitative systems pharmacology, which includes all the disciplines required for developing a successful drug.

Perspectives

Collaborating on this article with scientists from diverse disciplines and putting together this new concept was a true challenge and an honor and I hope that this article will stimulate more research into the areas that still need solutions in order to ground the CNS drug discovery process in a quantitative systems framework that we propose in this paper.

Dr. Katya Tsaioun
Johns Hopkins University

Read the Original

This page is a summary of: Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges, CPT Pharmacometrics & Systems Pharmacology, November 2019, Wiley, DOI: 10.1002/psp4.12478.
You can read the full text:

Read

Contributors

The following have contributed to this page